Alivus Life Sciences Limited share price
NSE: ALIVUS · ISIN INE03Q201024
Key numbers
- Market cap
- ₹ 16,766 Cr
- Current price
- ₹ 1,365.60
- 52-week high / low
- ₹ 1,494 / 819
- Stock P/E
- 27.8
- Book value
- ₹ 271.0
- Dividend yield
- 0.37%
- ROCE
- 24.2%
- ROE
- 18.4%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- 6.9%
- Profit growth (3 yrs)
- 6.5%
- 1-year return
- 38.9%
About Alivus Life Sciences Limited
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 650 | 602 | 673 | 689 | 640 |
| Operating profit | 198 | 172 | 231 | 215 | 212 |
| Net profit | 142 | 122 | 150 | 163 | 160 |
| EPS (₹) | 11.57 | 9.91 | 12.25 | 13.23 | 13.04 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- While growth in the GPL business is expected to remain flattish in FY '27, the business has been historically weighted towards the second half of the year and we expect a similar trend to play out this year, resulting in a stronger H2 performance.
- We also remain confident of sustaining EBITDA margins in the 30% to 32% range.
Growth & demand
- Our non-GPL business delivered strong growth of 26.5% year -on-year, driven by successful new product launches and strong demand across all geographies.
- At the s ame time, we expect the healthy growth momentum in the non-GPL business to continue, supported by a robust product pipeline, recent launches and sustained demand across all markets.
Margins & costs
- On the profitability front, a favou rable product mix and newer launches helped improve gross margins to 60.2%, an increase in 510 basis points year -on-year.
- Enhanced operational efficiencies and forex gains also supported 650 basis points Y-o-Y improvement in EBITDA margins to 36.6%.
Capex & expansion
- On the balance sheet and cash flow moment, our capex for the quarter stood at INR85 crores.
- So is this capacity enough for us to grow double digits for this year, you have gui ded 10% to 12% and hopefully, FY'28 also double digits.
Balance sheet & cash
- We generated a strong free cash flow of INR90 crores, leading to cash and cash equivalents including short -term investments of INR880 crores as of 30th June 2026.
- As far as the cash flows are concerned, cash flows are robust.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.